NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors
New Data Coming Out Of AASLD
Boston Pharma may be rising in the FGF21 space, while Viking could be formidable competition for Madrigal in the THRβ agonist class. Akero will soon report potentially groundbreaking data in cirrhotic NASH.
